1. Introduction {#s0005}
===============

Western life style with excessive food intake and reduced physical activity is the leading cause of metabolic syndrome, including the following criteria; increased abdominal waist line, elevated triglycerides, low HDL cholesterol levels, high blood pressure and insulin resistance ([@bb0045]). Metabolic syndrome is a strong predictor for the development of cardiovascular disease (CVD), the leading cause of mortality world-wide ([@bb0105]). The major risk factor for CVD is hypercholesterolemia, and therefore statins are the major therapeutic drugs used to prevent cardiovascular episodes. Statins decrease levels of low density lipoprotein cholesterol (LDL) in the blood by inhibiting 3-hydroxy-3-methyl-glutaryl coenzyme-A (HMG-CoA). Although proven beneficial for the treatment of CVD, there is emerging evidence suggesting increased incidence of new-onset diabetes with statin use ([@bb0010], [@bb0075], [@bb0105], [@bb0115], [@bb0125], [@bb0135]). The first study to report an increased incidence of diabetes with statins was the JUPITER trial, a double-blind randomized study comparing subjects assigned to rosuvastatin 20 mg or placebo ([@bb0075], [@bb0115]). Rosuvastatin has hydrophilic properties and is more potent in reducing cholesterol levels than pravastatin and simvastatin ([@bb0095]).

The mechanisms behind increased diabetes incidence by statins remain to be investigated. A follow-up study in the METSIM cohort showed association between increased risk of diabetes with statins and impaired insulin sensitivity and insulin secretion ([@bb0010]). Others suggest improved insulin sensitivity by statins ([@bb0050], [@bb0085], [@bb0100], [@bb0140]). Insulin resistance leads to an increased pressure on the beta cells to secrete more insulin. When the beta cell response is insufficient, fasting and postprandial hyperglycemia develops ultimately leading to type 2 diabetes. Normally, increased blood glucose stimulates beta cells to secrete insulin through a Ca^2 +^ dependent process. We have previously demonstrated that cholesterol in the plasma membrane of the beta cell is essential for insulin secretion, and removal reduces glucose-stimulated insulin secretion by \> 50% ([@bb0155]). Thus, although elevated blood cholesterol is deleterious, sufficient cholesterol levels in cell membranes are vital. Hence, the balance between circulating and cellular levels needs to be tightly controlled. It is not known whether statins influence glucose metabolism through this balance or through a direct effect on beta cells. In favor of the latter, studies performed in cell lines suggest effects on small G-binding proteins ([@bb0065]) and reduced voltage-dependent Ca^2 +^ influx ([@bb0085], [@bb0130], [@bb0165]). Moreover, acute experiments with rosuvastatin *in vitro* in human islets have shown ultrastructural changes ([@bb0005]) and reduced insulin secretion ([@bb0170]).

The High Fat Diet (HFD) fed mouse is a widely used model to study insulin resistance ([@bb0160]), and the phenotype has many of the risk factors associated with metabolic syndrome ([@bb0045]). The mice are obese, and have elevated cholesterol and blood glucose. The blood glucose is only slightly increased since the HFD mouse compensate with increased insulin secretion, further fueling weight gain and insulin resistance ([@bb0160]). As many patients treated with statins have a high BMI, it is of interest to investigate the mechanisms explaining the effect of statin treatment on glucose homeostasis in HFD mice compared to mice fed a normal diet (ND). Here we have studied the integrated role of rosuvastatin on glucose homeostasis and aimed to understand the cellular mechanisms by which rosuvastatin acts on insulin secretion and glucose uptake.

2. Materials and Methods {#s0010}
========================

2.1. Animals {#s0015}
------------

C57BL/6 female mice were delivered from Taconic, Denmark at 8 weeks. Mice were allowed to adapt to the surrounding for one week before given high-fat diet (HFD) and matched low-fat normal diet (ND) (Research Diets Inc, New Brunswick, USA). The ND contained the same ingredients with a closely matched composition to the HFD formula. After 4 weeks on ND or HFD mice part of the mice were given rosuvastatin (0.2 mg/mice/day; LKT Laboratories, MN, USA) in the drinking water for the rest of the study period. At the end of the study mice were sacrificed and tissues were collected for further analysis. The procedures used in the *in vitro* and *in vivo* studies were approved by the ethical committee of Lund/Malmö.

2.2. OGTT and *In Vivo* Measurements {#s0020}
------------------------------------

The *in vivo* study was performed according to the study plan (Fig. S1). OGTT was performed at week 0, 4, 8 and 12. Prior to OGTT mice were fasted for 4--6 h. [d]{.smallcaps}-Glucose was administered at 75 mg/mouse by oral gavage and blood was sampled from the vena saphena at 0, 15, 30, 60 and 120 min. The samples were immediately analyzed for glucose using a blood glucose meter (Accu-Check Aviva, Roche Diagnostics Scandinavia AB, Bromma, Sweden). Plasma samples were stored at − 20 °C until being assayed for insulin ELISA (Mercordia, Uppsala, Sweden). Blood samples to measure total cholesterol, triglycerides and HDL were collected at week 6, 10 and 12 and levels were determined using commercially available kits (HDL: HDL-cholesterol plus direct method (\#981823); total cholesterol: InfinityTM Cholesterol Liquid Stable Reagent (\#TR13421); triglycerides: InfinityTM Triglycerides Liquid Stable Reagent (\#TR22421); Thermo Fisher Scientific, VA, USA). LDL was estimated according to the manufacturer\'s instructions.

2.3. Isolation of Islets and Hormone Release Assays {#s0025}
---------------------------------------------------

Pancreatic islets were isolated by collagenase digestion and hand-picked prior to insulin secretion measurements. Insulin secretion was measured in static batch incubations as previously described ([@bb0155]). Briefly, islets were pre-incubated in 1 mM glucose for 30 min followed by 1 h incubation in Krebs-Ringer bicarbonate buffer (pH = 7.4) with 10 mM HEPES, 0.1% bovine serum albumin and variable glucose as indicated (5.6, 11.1, and 16.7 mM). In some experiments the buffer was supplemented with 0.1 μM GLP-1 (Bachem, Bubendorf, Switzerland) or 50 mM KCl (equimolar substituted for NaCl), respectively. Total insulin islet content was determined after extraction with acidic ethanol. Insulin secretion and islet content was measured using Radio Immuno Assay (RIA; Millipore, Solna, Sweden).

2.4. Ultrastructural Analysis {#s0030}
-----------------------------

Mouse islets were fixed in 2.5% glutaraldehyde in freshly prepared Millonig\'s buffer and post-fixed in 1% osmium tetroxide before being dehydrated, embedded in AGAR 100 (Oxford Instruments Nordiska AB, Johanneshov, Sweden) and cut into ultrathin sections (70--90 nm). The sections were put on Cu-grids and contrasted using uranyl acetate and lead citrate. The islet containing sections were examined in a JEM 1230 electron microscope (JEOL-USA, Inc., Peabody, USA). Micrographs were analyzed with respect to the intracellular granule distribution as described elsewhere ([@bb0155]).

2.5. Imaging and Ca^2 +^ Measurements {#s0035}
-------------------------------------

Imaging of insulin and glucagon staining was performed using confocal microscopy imaging (Zeiss LSM 510). For calcium imaging islets were loaded with 4 μM Fura 2-AM (TefLabs, Austin, USA) for 40 min followed by 30 minutes de-esterification in imaging buffer at pH 7.4 (mM: KCl 3.6, MgSO~4~ 0.5, CaCl~2~ 2.5, NaCl 140, NaHCO~3~, NaH~2~PO~3~ 0.5, HEPES 5). Imaging was performed with a Polychrome V monochromator (TILL Photonics, Graefelfing, Germany) on a Nikon Eclipse Ti Microscope (Nikon, Tokyo, Japan) equipped with an ER-BOB-100 trigger, an iXON3 camera, and iQ2 software (Andor Technology, Belfast, UK). Recordings were performed at one frame per second at 37 °C under perfusion at 1 ml/min. A region was marked around each islet and the ratio of fluorescence emission intensity per unit area (μm^2^) at 340 nm (exposure 150 ms) and 380 nm (exposure 100 ms) was recorded. Parameters analyzed are described in Suppl Table 1.

2.6. Isolation and Glucose Uptake in Primary Adipocytes {#s0040}
-------------------------------------------------------

Primary adipose cells were isolated from epididymal adipose tissue as previously described ([@bb0120]). The isolated cells were suspended (5% suspension) in Krebs-Ringer (KRH) medium containing 25 mM HEPES pH 7.4, 200 nM adenosine, 2 mM glucose and 3% BSA (w/v), and glucose uptake measured as previously described ([@bb0040]). Briefly, cells were incubated in KRH medium (37 °C, shaking water bath) in triplicates with or without insulin (28 nM) for 30 min, followed by addition of [d]{.smallcaps}-^14^C(U)-glucose (2.5 μl/ml, NEC042, Perkin Elmer), and incubated for 30 min. The uptake was terminated by spinning 300 μl of each cell suspension in microtubes containing 80 μl dinonylphtalate oil. The cell fraction was collected, dissolved in scintillation fluid (Optima Gold, Perkin Elmer, Upplands Väsby, Sweden) and subjected to scintillation counting.

2.7. mRNA Expression Analysis {#s0045}
-----------------------------

Pancreatic islets were lysed in Qiazol (Qiagen, Sollentuna, Sweden) and homogenized by vortexing. Total RNA was extracted using miRNeasy®Mini Kit protocol (Qiagen) and RNA concentration was measured on a NanoDrop (Thermo Scientific, Göteborg, Sweden). High Capacity cDNA Reverse Transcriptase Kit (Life Technologies, Stockholm, Sweden) was used to generate RT-PCR according to the manufacturer\'s protocol.

The QuantStudio™ 7 Flex Real-Time PCR System (Life Technologies) was used to performed qPCR according to the TaqMan®Universal PCR Master Mix I protocol (Life Technologies) using the following primers from TaqMan®Gene Expression Assays; *SERCA2* (Mm01201431_m1), *SERCA3* (Mm00443898_m1), *Sel1l* (Mm01326442_m1), *CHOP* (Mm01135937_m1), and *Calb1* (Mm00486647_m1). Gene expression was normalized using *Hprt* (Mm004469_m1) and *Ppia* (Mm00478295_m1) as reference genes with the ΔΔCt method.

2.8. Western Blot Analysis {#s0050}
--------------------------

Intact soleus muscle tissues were homogenized with a polytron (Omni International TH, Bebensee, Germany) in lysis buffer containing 50 mM Tris/HCl pH 7.5, 1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium-β-glycerophosphate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 1% NP-40, 1 mM dithiothreitol (DTT), and complete protease inhibitor cocktail (one tablet/50 ml). Lysates were centrifuged for 15 min at 10,000 ×* g* and protein concentrations were determined by Bradford assay. Adipose tissue lysates were heated at 95 °C for 2 min in SDS sample buffer, subjected to polyacrylamide gel electrophoresis on pre-cast gradient gels (Biorad, Sundbyberg, Sweden) followed by electrotransfer to nitrocellulose membrane. According to Bradford protein quantification 10 μg protein was loaded per sample. Membranes were blocked for 30 min in 50 mM Tris/HCl pH 7.6, 137 mM NaCl and 0.1% (w/v) Tween-20 (TBS-T) containing 10% (w/v) skim milk. The membranes were then probed with indicated antibodies in TBS-T containing 5% (w/v) milk or 5% (w/v) BSA, for 16 h at 4 °C. Detection was performed using horseradish peroxidase conjugated secondary antibodies and the chemiluminescence reagent. The signal was visualized using a BioRad Image camera and band intensities quantified using BioRad Imaging software (Biorad, CA, USA).

2.9. Calculations and Statistical Analysis {#s0055}
------------------------------------------

Data from the OGTT measurements was analyzed as described in ([@bb0090]). In short ISI *\_Comp*, a measure of insulin sensitivity in rodents adapted from Matsuda\'s method ([@bb0070]), was calculated as 10,000/(√\[G~0~ × I~0~ × G~mean~ × I~mean~\]) where G~0~ and I~0~ are starting values for glucose and insulin, and G~mean~ and I~mean~ are average glucose and insulin values during the 120 min. Beta cell function was estimated as the BCI~oral~ using total AUC for insulin and glucose measured during the 120 min (tAUC_ins/tAUC_gluc) or during the first 30 min (BCI~oral~ 0--30). Beta cell function was also estimated using the suprabasal measures of AUC, sAUC, for insulin and glucagon (sBCI~oral~).

Data are presented as mean ± SEM. Statistical significance was determined using two-way ANOVA or two-tailed Student\'s *t*-test.

3. Results {#s0060}
==========

3.1. Reduced Insulin Sensitivity and Increased Insulin Secretion in HFD Mice {#s0065}
----------------------------------------------------------------------------

We were interested in comparing the effect of rosuvastatin under both normal diet (ND) and high fat diet (HFD) conditions. The ND was a low-fat diet matched in every way to the HFD composition except for the fat content. Mice were monitored for 12 weeks and repeated oral glucose tolerance tests (OGTTs) and cholesterol measurements were performed (see study design and Suppl Fig. 1 for details). After 4 weeks on ND or HFD, mice were given rosuvastatin (0.2 mg/mice/day) in the drinking water for the rest of the study period. Total cholesterol and LDL was significantly reduced after 2 weeks of treatment (study week 6) and the levels continued to decrease throughout the study in mice given rosuvastatin as compared to control mice (Suppl Fig. 2). Weight, food, and water intake was monitored (Suppl Fig. 3). HFD mice increased body weight gain compared to ND independent of rosuvastatin.

Mice on HFD for 4 weeks had significantly higher blood glucose and insulin response *in vivo* at all time-points measured compared to mice on ND ([Fig. 1](#f0005){ref-type="fig"}A-B) and *ISI*\_*Comp*, an estimate of insulin sensitivity, was reduced by \~ 60% ([Table 1](#t0005){ref-type="table"}). Confirming previous findings ([@bb0160]) that HFD mice have increased insulin resistance. Blood glucose (area under the curve for glucose (tAUC~gluc~)) as well as insulin levels (tAUC~ins~) were increased, with beta cell function (BCI~oral~) being enhanced ([Table 1](#t0005){ref-type="table"}). This pattern was persistent throughout the study.

To assess beta cell function in more detail *in vitro* insulin secretion was performed on islets isolated at the end of the study ([Fig. 1](#f0005){ref-type="fig"}C-E). In agreement with the *in vivo* insulin secretion data, HFD mice had increased insulin content. At mRNA level *Ins2* was not affected and *Pdx1* was reduced by HFD ([Fig. 1](#f0005){ref-type="fig"}F). The increased insulin content was in line with ultrastructural data ([Fig. 1](#f0005){ref-type="fig"}G-I) and the total number of insulin granules was increased in HFD mice as compared to control mice (p \< 0.001; [Fig. 1](#f0005){ref-type="fig"}H). HFD also resulted in reduced number of docked granules (p \< 0.001; [Fig. 1](#f0005){ref-type="fig"}I). *In vitro* insulin secretion *per se* was not different in islets from ND and HFD mice but when compensated for the increased insulin content insulin secretion was significantly decreased.

3.2. Rosuvastatin Reduces Insulin Content and Impairs Ca^2 +^ Signaling in ND Mice {#s0070}
----------------------------------------------------------------------------------

Next we measured the effect of rosuvastatin on glucose homeostasis in ND mice. In OGTT measurements after 4 weeks of rosuvastatin treatment (study week 8) we observed a decrease in glucose levels during the first 30 min ([Fig. 2](#f0010){ref-type="fig"}A and [Table 1](#t0005){ref-type="table"}) reflecting an increase in insulin sensitivity (ISI\_*Comp*; [Table 1](#t0005){ref-type="table"}). We did not detect any significant glucose-induced changes in *in vivo* insulin secretion by rosuvastatin ([Fig. 2](#f0010){ref-type="fig"}B, D and [Table 1](#t0005){ref-type="table"}).

*In vitro*, islets from rosuvastatin treated mice had lower response to all stimulatory secretagogues tested, and the effect of rosuvastatin was found to be overall significant ([Fig. 2](#f0010){ref-type="fig"}E). Insulin content was reduced by \~ 25% in islets from rosuvastatin treated mice ([Fig. 2](#f0010){ref-type="fig"}F). There was no significant difference in insulin secretion when compensated for the reduced insulin content ([Fig. 2](#f0010){ref-type="fig"}G). Expression of Ins2 was not affected by rosuvastatin, but Pdx1 mRNA was significantly increased ([Fig. 1](#f0005){ref-type="fig"}F middle panel). However, the ultrastructural analysis did not reveal any effect by rosuvastatin on the total number of insulin granules ([Fig. 1](#f0005){ref-type="fig"}H). In agreement with a reduced insulin secretion the density of docked granules was significantly increased ([Fig. 1](#f0005){ref-type="fig"}I; ND *vs* ND_Ros). This accumulation of granules at the plasma membrane, suggests defects in the fusion process. Confocal analysis confirmed that the ultrastructure of the islet remained intact after rosuvastatin treatment (Suppl Fig. 4).

Insulin secretion is Ca^2 +^ dependent and uptake of glucose generates oscillations consisting of a first rapid Ca^2 +^ peak followed by a nadir and subsequent consistent oscillations, and impaired Ca^2 +^ response thus directly affects insulin secretion. We measured Ca^2 +^ oscillations in islets from ND mice with and without rosuvastatin ([Fig. 3](#f0015){ref-type="fig"}A) and indeed several parameters in the Ca^2 +^ response were changed in islets from rosuvastatin treated mice ([Fig. 3](#f0015){ref-type="fig"}B). Normally, glucose-stimulation (16.7 mM) reduces the beta cell Ca^2 +^ concentration transiently reflecting Ca^2 +^ uptake into ER (A~d~). This dip was reduced in the rosuvastatin treated mice. Moreover, there was a significant increase in total Ca^2 +^ influx (AUC_tot). The frequency of oscillations did not change with rosuvastatin, but the reduction in Ca^2 +^ after the first peak (C~2~) was significantly smaller (Suppl Table 1; p \< 0.001).

The impaired Ca^2 +^ response and particularly the reduced re-uptake of Ca^2 +^ to ER in rosuvastatin treated mice prompted us to investigate the expression of ER-related genes; *SERCA2*, *SERCA3*, *Sel1l* and *CHOP* ([@bb0015], [@bb0025], [@bb0110]) together with *Calb1*, a gene we previously suggested to be involved in Ca^2 +^ buffering ([@bb0020]). Rosuvastatin reduced the expression of *CHOP* in mice on ND, but had no effect on the expression of the other genes investigated ([Fig. 3](#f0015){ref-type="fig"}C).

3.3. Rosuvastatin Improves Glucose Uptake and Reduces Insulin Secretion in HFD Mice {#s0075}
-----------------------------------------------------------------------------------

We next investigated effects of rosuvastatin on HFD mice. OGTTs revealed no further effect on either blood glucose or the insulin response by rosuvastatin after 4 weeks of rosuvastatin (study week 8; [Fig. 4](#f0020){ref-type="fig"}A--B). However, after 8 weeks on rosuvastatin (study week 12; [Fig. 4](#f0020){ref-type="fig"}C--D) the acute insulin response was significantly lower ([Fig. 4](#f0020){ref-type="fig"}D, [Table 1](#t0005){ref-type="table"}). The insulin response to glucose was highly variable in the HFD mice treated with rosuvastatin (Suppl Fig. 6), and 4 out of 13 mice had no insulin response at all. Since HFD increased both insulin and glucose levels, we also analyzed the suprabasal AUC for insulin and glucose (sAUC~gluc~ and sAUC~ins~), both indicators of the response to glucose stimulation above basal levels. sAUC~ins~ was reduced in the rosuvastatin treated mice on HFD, and sBCI~oral~ was significantly decreased. The effects were even more pronounced if values were measured during the first 30 min (sAUC~ins~(0--30) and BCI~oral~(0--30); [Table 1](#t0005){ref-type="table"}).

Insulin secretion *in vitro* was not reduced by rosuvastatin in any condition investigated in the HFD mice ([Fig. 4](#f0020){ref-type="fig"}E), but insulin content was slightly reduced ([Fig. 4](#f0020){ref-type="fig"}F). Therefore, insulin secretion per insulin content ([Fig. 4](#f0020){ref-type="fig"}G) was increased. Even though insulin content was reduced the density of insulin granules was the same in HFD and HFD rosuvastatin treated mice ([Fig. 1](#f0005){ref-type="fig"}h). However, the number of docked granules was significantly increased ([Fig. 1](#f0005){ref-type="fig"}i).

We also investigated the expression of ER-related genes and *Calb1* in mice on HFD with or without rosuvastatin treatment (Suppl Fig. 5). HFD diet reduced expression of *SERCA3*, *Sel1l*, *CHOP* and *Calb1* compared to ND mice (Suppl Fig. 5A). Rosuvastatin did not have any further effect in the HFD mice (Suppl Fig. 5B).

3.4. Rosuvastatin Improves Insulin Sensitivity and Increases Glucose Uptake {#s0080}
---------------------------------------------------------------------------

We followed the calculated insulin sensitivity estimated as *ISI_Comp* ([Table 1](#t0005){ref-type="table"}) over time for the four different conditions investigated ([Fig. 5](#f0025){ref-type="fig"}A), confirming previous observations that HFD reduce insulin sensitivity. This impairment in insulin sensitivity was confirmed in isolated adipocytes where both basal and insulin stimulated glucose uptake was reduced in HFD mice ([Fig. 5](#f0025){ref-type="fig"}B).

In ND mice, insulin sensitivity was improved by rosuvastatin treatment (study week 8; 4 weeks with rosuvastatin) while in HFD mice there was a tendency towards improved insulin sensitivity after 8 weeks of rosuvastatin treatment although the difference had only borderline significance. The improved insulin sensitivity could be verified *in vitro* in isolated adipocytes, where rosuvastatin increased basal (none insulin-stimulated) glucose uptake in ND mice ([Fig. 5](#f0025){ref-type="fig"}C). Most importantly, both basal and insulin stimulated glucose uptake was increased in the rosuvastatin treated HFD group ([Fig. 5](#f0025){ref-type="fig"}D). Most blood glucose is disposed in skeletal muscle tissue, and in the soleus muscle, we observed increased protein levels of GLUT4 after rosuvastatin treatment in ND mice, whereas the levels were decreased by rosuvastatin in HFD mice ([Fig. 5](#f0025){ref-type="fig"}E--F). In addition, phosphorylated AMPK was significantly reduced in the HFD mice on rosuvastatin ([Fig. 5](#f0025){ref-type="fig"}E, G).

4. Discussion {#s0085}
=============

Several studies propose an association between new on-set diabetes and statin treatment ([@bb0010], [@bb0075], [@bb0105], [@bb0115], [@bb0125], [@bb0135]), but the precise mechanisms remain unknown. To obtain a better understanding of the possible cellular mechanisms by which statins influence glucose homeostasis we performed detailed analysis in mice on ND and HFD treated with rosuvastatin. Our data suggests dual effects on glucose homeostasis with improved insulin sensitivity and reduced insulin secretion.

Current literature is conflicting concerning the effects of rosuvastatin on insulin sensitivity. Some studies speak in favor of statins and suggest that it improves insulin sensitivity ([@bb0050], [@bb0085], [@bb0100], [@bb0140]), whereas others report that statin treatment leads to increased insulin resistance ([@bb0010], [@bb0055], [@bb0080]), and some that statins have no effects on insulin sensitivity ([@bb0035], [@bb0060]). Our data show that rosuvastatin improves insulin sensitivity. In our *in vivo* experiments this was most obvious in mice on ND, but we could observe a tendency also in the HFD mice. The effect could be dose dependent, since mice on ND, where the effect on insulin sensitivity was most pronounced, had slightly higher water intake. Our HFD mice became insulin resistant, and the effect of HFD seems to override any effect of rosuvastatin. Our *in vivo* data is supported by *in vitro* measurements showing increased adipose glucose uptake in both ND and HFD mice treated with rosuvastatin. Interestingly, rosuvastatin raised primarily basal but also insulin-dependent glucose uptake. Hence, our data are in agreement with improved insulin sensitivity. In adipose and muscle cells, glucose uptake is facilitated through insulin-regulated glucose-transporter GLUT4, some situated in clusters at the plasma membrane ([@bb0145]). In the basal state, only a few GLUT4 transporters are present at the membrane ([@bb0145]). Thus, it can be suggested that rosuvastatin either increases the basal GLUT4 translocation, possibly through membrane alteration, or affects mechanisms downstream of the insulin receptor. We observed that rosuvastatin increased GLUT4 protein levels in the soleus muscle of ND mice, whereas in HFD mice it decreased GLUT4 levels. This might explain the larger improvement of insulin sensitivity in rosuvastatin treated mice on ND as compared to HFD, since the majority of glucose uptake *in vivo* is through muscle ([@bb0150]). Insulin stimulation increases the number of GLUT4 in the plasma membrane, but muscle contraction also stimulates translocation of GLUT4 to the plasma membrane independent of insulin ([@bb0030]).

How could the reported increased incidence of new on-set diabetes with statins be explained? Knowledge regarding statin effects on beta cell function is scarce, except for a recent study suggesting impaired insulin secretion with statins ([@bb0010]). We therefore also investigated beta cell function in more detail *in vivo* and *in vitro*. Our data confirms a rosuvastatin-induced impairment of beta cell function and reduced insulin secretion *in vitro, but not in vivo*. The observed differences might be explained by absence of the complex integrated response from *e.g.* incretins and neuronal input in the *in vitro* insulin secretion measurements on isolated islets. *In vivo* the most pronounced effect was observed in HFD mice, and the increase in insulin secretion by HFD was counteracted by rosuvastatin. The *in vitro* insulin secretion measurements were presented both as per islet and per insulin content and insulin content data is also given. The data obtained when measuring insulin secretion per islet is the summed effect by changes in insulin content and effects on the insulin secretion process. When insulin is expressed as per insulin content this factor is taken into account and the changes measured are due to direct effects on the insulin secretion process. In the three different scenarios measured here this suggests that 1) HFD increases insulin content and inhibits the insulin secretion process; 2) rosuvastatin treatment in ND mice mainly reduces insulin content; and 3) rosuvastatin treatment in HFD mice reduces insulin content and amplifies the insulin secretion process.

How does then rosuvastatin disturb beta cell function? Our investigation shows a profound reduction of insulin content although the total number of granules remains unchanged. This is in agreement with experiments in MIN6 cells showing reduced insulin-synthesis *via* a disturbed metabolism ([@bb0175]). We could not detect any changes in *Ins2* mRNA, but still protein processing could be disturbed. The reduced insulin content together with the increased number of docked granules and disturbed Ca^2 +^ signaling shows that rosuvastatin has multiple cellular effects that contribute to the impaired insulin secretion. Disturbed Ca^2 +^ signaling can be due to impaired influx of Ca^2 +^ through voltage-dependent Ca^2 +^ channels. Indeed we have recently shown reduced Ca^2 +^ current in INS-1832/13 treated with rosuvastatin ([@bb0130]) and simvastatin has in other beta cell lines been demonstrated to reduce the Ca^2 +^ current ([@bb0165], [@bb0175]). Our Ca^2 +^ measurements show changes in the transient Ca^2 +^ response to glucose. The observed reduction in the Ca^2 +^ dip suggests an incipient ER-stress. In consonance, CHOP was reduced in ND mice suggesting a protective mechanism counteracting ER-stress. Atorvastatin has also been shown to reduce the expression of *CHOP* and other ER-stress markers ([@bb0015]).

In conclusion, we have demonstrated that rosuvastatin reduces blood glucose through improved insulin sensitivity. Therefore, rosuvastatin has an overall positive effect on glucose homeostasis. However, we observed deleterious effects on the beta cells *in vitro* which may be detrimental in the long run. More specifically, from a long term perspective an impaired beta cell function, with reduced insulin content and disturbed Ca^2 +^ signaling, will accelerate the risk of developing hyperglycemia. Hence, individuals susceptible to diabetes development are likely to be more sensitive to the negative effect of rosuvastatin treatment on beta cells, which could explain the association between increased risk of new-onset diabetes and statin treatment.
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![*In vivo* and *in vitro* parameters from mice on ND and HFD.\
(A) Blood glucose and (B) insulin in mice after 4 weeks on ND (top) and HFD (bottom). Data presented as mean ± SEM of N = 14--25 mice; \*\*p \< 0.01 and \*\*\*p \< 0.001 HFD *vs* ND using *t*-test for each time-point. For both glucose and insulin OGTT data: p \< 0.001 ND *vs* HFD using 2 way repeated measures ANOVA (C) insulin secretion and (D) insulin content in isolated islets from mice on ND with and without rosuvastatin as indicated. Islets were incubated for 1 h in 1 mM, 5.6 mM, 11.1 mM and 16.7 mM glucose in the absence or presence of 50 mM K^+^ or 100 nM GLP-1. N = 4 ain each group \*\*\*p \< 0.01 ND_Ros *vs* ND on effects of rosuvastatin (ordinary 2-way ANOVA). (E) Insulin secretion per insulin content from data in C--D. (F) Expression of *Ins2* and *Pdx1* in islet from ND and HFD with and without rosuvastatin. Data presented as mean ± SEM of N = 6 biological replicates,\*p \< 0.05 ND_Ros *vs* ND using *t*-test. (G) Ultrastructural images of beta cells from mice on ND (left) and HFD (right). Arrows indicate docked granules. PM - plasma membrane; g - granule. Scale bar 0.5 μm. (H--I) Histogram of calculated volume density (Nv) and surface density (Ns) from beta cells from mice on ND and HFD with and without rosuvastatin as indicated. Data are mean of 54--65 cells from N = 3 mice in each group, \*p \< 0.05 ND_Ros *vs* ND or HFD_Ros *vs* HFD using *t*-test.](gr1){#f0005}

![*In vivo* blood glucose levels and insulin during OGTT and *in vitro* insulin secretion in ND mice.\
(A) Blood glucose and (B) insulin at study week 8 in ND mice with and without rosuvastatin for 4 weeks. Data presented as mean ± SEM of N = 11--14 mice; for glucose OGTT data: p \< 0.01 ND *vs* HFD using 2 way repeated measures ANOVA (C--D). As in A--B, but at study week 12. Data presented as mean ± SEM of N = 9--14 mice; for glucose OGTT data: p \< 0.071 ND *vs* HFD using 2 way repeated measures ANOVA (E) Insulin secretion and (F) insulin content in isolated islets from mice on ND with and without rosuvastatin. Islets were incubated for 1 h in 1 mM, 5.6 mM, 11.1 mM and 16.7 mM glucose in the absence or presence of 50 mM K^+^ or 100 nM GLP-1 as indicated. (G) Insulin secretion per insulin content from data in E--F. Data are mean from N = 4 mice, \*\*p \< 0.01 ND_Ros *vs* ND on effects of rosuvastatin (2-way ANOVA).](gr2){#f0010}

![Ca^2+^ measurements on islets on ND with and without rosuvastatin.\
(A) Calcium measurements on islets from mice on ND (left) and ND with rosuvastatin (right). Oscillations were stimulated by addition of 16.7 mM glucose as indicated. (B) Histogram of analysis of the Ca^2 +^ trace in A. AUC~dip~ -- area of initial dip in Ca^2 +^ before the first Ca^2 +^ peak (below baseline); AUC~tot~ -- total area under the graph; D~0~ - delay response to 16.7 mM glucose; D~1~ -- delay response to 2.8 mM glucose as indicated in A. Data are presented as of N = 20--22 islets, \*p \< 0.05, \*\*p \< 0.01 and \*\*\*p \< 0.001 ND *vs* ND_Ros using students *t*-test. (C) Expression of *SERCA2*, *SERCA3*, *Sel1l*, *CHOP* and *Calb1* in islet from ND mice with and without rosuvastatin. Data presented as mean ± SEM of N = 6 biological replicates; \*p \< 0.05 ND *vs* ND_Ros using students *t*-test.](gr3){#f0015}

![*In vivo* blood glucose levels and insulin during OGTT and *in vitro* insulin secretion in HFD mice with and without rosuvastatin.\
(A) Blood glucose and (B) insulin at study week 8 in HFD mice with and without rosuvastatin for 4 weeks. Data presented as mean ± SEM of N = 9--13 mice (C--D). As in A--B, but at study week 12. Data presented as mean ± SEM of N = 9--14 mice (E). Insulin secretion and (F) insulin content in isolated islets from mice on HFD with and without rosuvastatin. Islets were incubated for 1 h in 1 mM, 5.6 mM, 11.1 mM and 16.7 mM glucose in the absence or presence of 50 mM K^+^ or 100 nM GLP-1 as indicated. (G) Insulin secretion per insulin content from data in E--F. Data are presented as mean ± SEM of N = 4 mice, \*p \< 0.05 HFD *vs* HFD_Ros on effects of rosuvastatin using 2-way ANOVA.](gr4){#f0020}

![Insulin sensitivity and glucose uptake in ND and HFD mice with or without rosuvastatin.\
(A) Insulin sensitivity (ISI\_*Comp*) in ND and HFD mice treated with and without rosuvastatin. Data are presented as mean ± SEM of 7--25 mice (see [Table 1](#t0005){ref-type="table"}), \*\*\*p \< 0.001 HFD *vs* ND or HFD_Ros *vs* ND_Ros; ††p \< 0.01 ND_Ros *vs* ND using *t*-test. (B) Glucose uptake in adipocytes from mice on ND and HFD. Uptake was measured in absence (basal) and presence of insulin (insulin). Data are mean ± SEM of N = 4 mice. (C) Glucose uptake in adipocytes from mice on ND without (Ctrl) and with rosuvastatin. Uptake was measured in absence (basal) and presence of insulin (insulin). White -- ND, grey - ND_Ros; \*\*\*p \< 0.001 ND_Ros *vs* ND using *t*-test. (D) Glucose uptake in adipocytes from mice on HFD with and without rosuvastatin. Uptake was measured in the absence and presence of insulin. Grey bar-HFD; black bar -- HFD_Ros. \*p \< 0.05, \*\*p \< 0.01 HFD_Ros *vs* HFD. (E) Western blot analysis of pAMPK (AMPK p172), AMPK tot, GLUT4 and actin in the soleus muscle of mice on ND and HFD with or without rosuvastatin as indicated. Data presented is from 4 groups/mice per condition, 10 μg protein per lane. (F) Summary of data in E. Histogram of GLUT4 levels normalized to actin (left) and (G) phosphorylated AMPK (AMPK p172) normalized to total AMPK (AMPK tot) in the soleus muscle under the 4 different conditions investigated. Data are presented as mean ± SEM of N = 4 biological replicates in each group, \*p \< 0.05, \*\*p \< 0.01 *vs* without rosuvastatin using *t*-test.](gr5){#f0025}

###### 

Measured and calculated values from the OGTT. Values are estimated according to Pacini and co-workers ([@bb0090]). tAUC_gluc -- total area under curve for glucose, sAUC\_ gluc -- suprabasal area under curve for glucose, tAUC_ins -- total area under curve for insulin, sAUC\_ ins -- suprabasal area under curve for insulin, D_ins_0--15 -- Insulin response first 15 min, BCI -- beta cell function based on total area, sBCI - suprabasal beta cell function based, ISI\_*Comp* - insulin resistance. ND - normal diet, HFD - high fat diet, ND_Ros - ND with rosuvastatin, HFD_Ros - HFD with rosuvastatin. Data are presented as mean ± S.E. and the number of mice in each group were for week 0 N = 17--52, week 4 N = 12--25, week 8 N = 7--14 and week 12 N = 9--15. \*p \< 0.05, \*\*p \< 0.01 and \*\*\*p \< 0.001 HFD *vs* ND or HFD_Ros *vs* ND_Ros; † p \< 0.05, ††p \< 0.01 and †††p \< 0.001 ND_Ros *vs* ND or HFD_Ros *vs* HFD.

Table 1

                              Week 0       Week 4       Week 8           Week 12                                                                                                       
  --------------------------- ------------ ------------ ---------------- ------------ ---------------- ----------------- ----------------- ------------ ------------ ----------------- -----------------
  Basal glucose (t = 0)       8.1 ± 0.5    7.9 ± 0.2    9.6 ± 0.3^⁎⁎^    7.6 ± 0.3    6.4 ± 0.6        8.0 ± 0.9         10.0 ± 0.4^⁎⁎⁎^   6.4 ± 0.2    5.9 ± 0.2    8.6 ± 0.3^⁎⁎⁎^    8.9 ± 0.3^⁎⁎⁎^
  tAUC_gluc (∗ 10^2^)         17.1 ± 0.6   17.6 ± 1.0   23.9 ± 1.2^⁎⁎^   15.4 ± 0.1   12.4 ± 0.5       24.8 ± 1.6^⁎⁎⁎^   22.9 ± 1.7^⁎⁎⁎^   14.9 ± 1.2   12.2 ± 0.7   19.8 ± 0.9^⁎⁎^    19.7 ± 0.9^⁎⁎⁎^
  tAUC_gluc_0--30 (∗ 10^2^)   4.4 ± 0.1    4.6 ± 0.2    5.6 ± 0.2^⁎⁎^    4.7 ± 0.2    3.3 ± 0.3^††^    4.9 ± 0.6         4.7 ± 0.6^⁎^      4.4 ± 0.3    3.9 ± 0.2    5.5 ± 0.1^⁎⁎⁎^    5.4 ± 0.2^⁎⁎⁎^
  sAUC_gluc (∗ 10^2^)         7.4 ± 0.7    8.1 ± 0.9    12.3 ± 1.2^⁎⁎^   6.3 ± 1.0    4.1 ± 0.4        13.8 ± 1.5^⁎⁎⁎^   11.0 ± 1.9^⁎⁎^    7.3 ± 1.4    5.1 ± 0.7    9.5 ± 1.0         9.0 ± 0.8^⁎⁎^
  sAUC_gluc_0--30 (∗ 10^2^)   1.9 ± 0.1    2.3 ± 0.2    2.7 ± 0.2^⁎^     2.4 ± 0.2    1.5 ± 0.2^†^     2.8 ± 0.4         2.5 ± 0.3^⁎⁎^     2.4 ± 0.3    2.1 ± 0.1    2.9 ± 0.1         2.8 ± 0.2^⁎^
  D_ins_0--15                 16 ± 3       9.1 ± 2.5    19.8 ± 3.8^⁎^    18.6 ± 3.4   15.2 ± 2.9       15.6 ± 3.8        20.8 ± 4.3        14.5 ± 2.5   14.0 ± 2.6   28.2 ± 2.7^⁎⁎^    12.4 ± 3.9^††^
  tAUC_ins (∗ 10^3^)          16.0 ± 1.6   12.0 ± 0.9   29.5 ± 3.7^⁎⁎^   14.8 ± 0.7   16.9 ± 0.6       33.1 ± 3.2^⁎⁎⁎^   36.3 ± 3.2^⁎⁎⁎^   13.2 ± 0.9   14.3 ± 0.9   47.7 ± 4.2^⁎⁎⁎^   46.8 ± 6.0^⁎⁎⁎^
  tAUC_ins_0--30 (∗ 10^3^)    6.4 ± 0.8    4.3 ± 0.7    9.8 ± 1.3^⁎⁎^    6.8 ± 0.5    5.7 ± 0.6        10.2 ± 0.6^⁎^     12.6 ± 0.7^⁎⁎^    5.8 ± 0.6    5.8 ± 0.6    17.1 ± 0.5^⁎⁎⁎^   15.6 ± 0.5^⁎⁎⁎^
  sAUC_ins                    6.7 ± 1.4    3.7 ± 0.5    9.7 ± 3.2        4.6 ± 1.0    4.9 ± 0.9        7.8 ± 4.0         5.6 ± 1.9         3.1 ± 1.0    4.5 ± 1.1    8.1 ± 3.4         − 3.8 ± 5.4^†^
  sAUC_ins_0--30              4.1 ± 0.8    2.3 ± 0.5    5.0 ± 1.0^⁎^     4.3 ± 1.0    3.5 ± 0.5        3.9 ± 1.7         4.9 ± 1.7         3.2 ± 0.6    3.4 ± 0.6    7.3 ± 0.5^⁎⁎^     2.8 ± 0.5^†††^
  BCI_oral                    11.0 ± 1.0   7.0 ± 0.9    12.6 ± 1.6^⁎^    10.9 ± 0.6   10.8 ± 0.5       14.4 ± 2.8        16.5 ± 2.3^⁎⁎^    10.0 ± 0.7   10.8 ± 0.7   25.2 ± 2.6^⁎⁎⁎^   25.0 ± 4.1^⁎⁎^
  BCI_oral_0--30              16.9 ± 1.9   9.7 ± 1.6    18.7 ± 2.4^⁎^    16.1 ± 1.6   15.4 ± 1.5       19.0 ± 3.7        21.9 ± 3.4        14.2 ± 1.4   14.4 ± 1.3   31.0 ± 3.5^⁎⁎⁎^   29.7 ± 4.3^⁎⁎^
  sBCI_oral                   16.8 ± 3.9   5.1 ± 0.9    10.1 ± 3.0       13.5 ± 4.4   12.7 ± 2.5       8.8 ± 6.5         8.0 ± 5.5         6.5 ± 2.0    8.6 ± 2.3    10.1 ± 4.3        − 3.3 ± 5.8^†^
  sBCI_oral_0--30             38.7 ± 9.0   11.9 ± 3.0   32.2 ± 11.0      22.2 ± 4.4   21.9 ± 4.1       16.1 ± 7.4        19.3 ± 7.6        15.7 ± 2.5   16.1 ± 2.8   26.6 ± 3.6^⁎⁎⁎^   8.3 ± 4.0^††^
  ISI\_*Comp*                 9.8 ± 0.8    10.5 ± 0.9   4.3 ± 0.4^⁎⁎⁎^   9.4 ± 0.5    11.3 ± 0.6^††^   3.6 ± 0.8^⁎⁎⁎^    2.9 ± 0.5^⁎⁎⁎^    10.9 ± 0.7   10.7 ± 0.5   2.5 ± 0.3^⁎⁎⁎^    2.7 ± 0.5^⁎⁎⁎^

[^1]: Shared co-senior authorship.
